Apply to trial NCT07467447

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening